Health

Time to lift the blindfold on medicine prices

Over the past years, the exorbitant prices of new medicines have been making headlines across Europe. Before a new medicine hits a national market, there are usually price negotiations between the drug manufacturer and the national authority. However, there is currently an asymmetry of information in these talks to the disadvantage of national authorities, who must largely negotiate in the dark.

As consumers are faced with a growing amount of information from different sources, we advocate for high quality and non-promotional information about health products.

The ageing of the population, rising healthcare costs and the economic crisis are challenging the sustainability of healthcare systems and consumers’ access to treatments.

Health scandals such as the weight-loss drug Mediator and the faulty PIP breast implants keep undermining consumers’ confidence in the safety of available health products and their oversight by the competent authorities.

Ensure consumers have access to high quality healthcare in all EU Member States
Guarantee consumers benefit from safe and innovative treatments
Allow consumers to make informed choices regarding their health